Design, synthesis and biological evaluation of (Quinazoline 4-yloxy)acetamide and (4-oxoquinazoline-3(4H)-yl)acetamide derivatives as inhibitors of Mycobacterium tuberculosis bd oxidase.
(4-oxoquinazoline-3(4H)-yl)acetamide
(Quinazoline 4-yloxy)acetamide
Mycobacterium tuberculosis bd-oxidase
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
15 Nov 2022
15 Nov 2022
Historique:
received:
25
05
2022
revised:
25
07
2022
accepted:
25
07
2022
pubmed:
17
8
2022
medline:
21
9
2022
entrez:
16
8
2022
Statut:
ppublish
Résumé
New chemical scaffolds with novel mechanism of action are urgently needed for the treatment of drug resistant tuberculosis. The oxidative phosphorylation pathway of Mycobacterium tuberculosis consists of multiple clinically validated drug targets. This pathway can function through any one of the two terminal oxidases-the proton pumping cytochrome bc
Identifiants
pubmed: 35973312
pii: S0223-5234(22)00541-4
doi: 10.1016/j.ejmech.2022.114639
pii:
doi:
Substances chimiques
Acetamides
0
Amides
0
Cytochromes
0
Protons
0
Quinazolines
0
Adenosine Triphosphate
8L70Q75FXE
Oxidoreductases
EC 1.-
Electron Transport Complex IV
EC 1.9.3.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
114639Informations de copyright
Copyright © 2022 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.